aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Abcuro, founded with a mission to develop innovative treatments for autoimmune diseases and cancer, is a clinical-stage biotechnology company. The company's vision is to harness the precision targeting of highly cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1. Abcuro's leading product, ABC008, is an investigational monoclonal antibody designed to selectively deplete these cytotoxic cells, offering potential treatment for conditions like Inclusion Body Myositis (IBM), a chronic progressive disorder.
Notable figures affiliated with Abcuro include Mark Pruzanski, M.D., who serves as the Chairman of its Board of Directors. The company has made significant strides in advancing ABC008 through clinical trials, positioning it as a first-in-class therapeutic candidate. Abcuro's impact lies in its targeted approach to modulating immune responses, which holds promise for improving the lives of patients suffering from debilitating autoimmune diseases and certain cancers.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Therapeutics, Biotechnology
Technology
Biotech
Tags
SaaS
Model Types
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Abcuro founded?
Abcuro was founded in 2015.
Where is Abcuro's headquarters located?
Abcuro's headquarters is located in Newton, MA, US.
When was Abcuro's last funding round?
Abcuro's most recent funding round was for $155M (USD) in August 2023.
How many employees does Abcuro have?
Abcuro has 33 employees as of Feb 5, 2024.
How much has Abcuro raised to-date?
As of July 05, 2023, Abcuro has raised a total of $214.8M (USD) since Aug 17, 2023.
Add Comparison
Total Raised to Date
$214.8M
USD
Last Update Aug 17, 2023
Last Deal Details
$155M
USD
Aug 17, 2023
Series B
Total Employees Over Time
33
As of Feb 2024
Abcuro Address
55 Chapel Street
suite 200
Newton,
Massachusetts
02458-1070
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts